LMP Capital & Income Fund's (SCD) 9.2% yield and distribution outlook: coverage, risk profile, and Franklin Templeton’s ...

Gene therapy and small molecules are opening the door to new curative approaches, but access continues to be a barrier for ...

81.7% of patients were on an SGLT2 inhibitor 74.7% of patients were on an ARNI 95.1% of patients were on a beta-blocker 83.1% of patients were on an MRA Despite high use of GDMT, the rate of ...

Conventional ECG-based algorithms could contribute to sudden cardiac death (SCD) risk stratification but demonstrate moderate predictive capabilities. Deep learning (DL) models use the entire digital ...

A new report based on patient focus groups suggests many clinicians can do more to help patients with sickle cell disease (SCD) feel heard and understood. People with sickle cell disease (SCD) say a ...

A cross-sectional analysis assessed the birth prevalence of sickle cell disease (SCD) alongside data on social vulnerability to highlight the needs of communities impacted by SCD. SCD, a blood ...

The LMP Capital and Income Fund (SCD) is a closed-end fund that aims to provide its investors with a high level of current income along with capital appreciation through investments in a portfolio ...

Because SCD can impair blood and oxygen delivery to any part of the body, it can cause a wide range of complications, including anemia, blood clots, and stroke. It can also damage organs, such as the ...